Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 19, 26 | Scherer Mary C. | officer: Chief Accounting Officer | S-Sale | 100 @ $237.40 | $23.74K |
Daily · Wilder smoothing
| Aug 19, 26 |
| Scherer Mary C. |
| officer: Chief Accounting Officer |
| S-Sale |
| 2,202 @ $237.39 |
| $522.7K |
| Aug 18, 26 | Hollar Jason M. | officer: Chief Executive Officer | S-Sale | 21,407 @ $234.56 | $5.02M |
| Aug 18, 26 | Hollar Jason M. | officer: Chief Executive Officer | S-Sale | 29,915 @ $235.51 | $7.05M |
| Aug 18, 26 | Hollar Jason M. | officer: Chief Executive Officer | S-Sale | 16,208 @ $236.54 | $3.83M |
| Aug 18, 26 | Hollar Jason M. | officer: Chief Executive Officer | S-Sale | 12,470 @ $237.25 | $2.96M |
| Aug 19, 26 | Hollar Jason M. | officer: Chief Executive Officer | S-Sale | 6,206 @ $233.22 | $1.45M |
| Aug 19, 26 | Hollar Jason M. | officer: Chief Executive Officer | S-Sale | 3,457 @ $234.29 | $809.9K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 63.17 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 85.40 | Oscillator | Sell |
| Williams %R (14) | -27.45 | Oscillator | Neutral |
| MACD (12, 26, 9) | 6.58 (Hist 1.70) | Oscillator | Strong Buy |
| Average Directional Index (14) | 25.58 (+DI 31.1 / -DI 18.6) | Trend | Strong Buy |
| EMA 20 | 244.30 | MA | Buy |
| SMA 20 | 240.42 | MA | Strong Buy |
| EMA 50 | 237.48 | MA | Strong Buy |
| SMA 50 | 236.31 | MA | Strong Buy |
| SMA 200 | 221.08 | MA | Strong Buy |
Stock news · updated daily
I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.
Cardinal Health (CAH) concluded the recent trading session at $257.55, signifying a +1.94% move from its prior day's close.
Cardinal Health (CAH) closed at $253.71 in the latest trading session, marking a +2.41% move from the prior day.
As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Cardinal Health (CAH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.
CAH enters fiscal 2027 with Pharma profit growth, emerging growth engines and efficiency gains offsetting revenue headwinds.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | 2.42 | 2.91 | Beat 20.2% | $63.67B |
| Apr 30, 2026 | 2.79 | 3.17 | Beat 13.6% | $60.94B |
| Feb 5, 2026 | 2.34 | 2.63 | Beat 12.4% | $65.63B |
| Oct 30, 2025 | 2.18 | 2.55 | Beat 17.0% | $64.01B |
| Aug 12, 2025 | 2.04 | 2.08 | Beat 2.0% | $60.16B |
| May 1, 2025 | 2.17 | 2.35 | Beat 8.3% | $54.88B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 1, 2026 | 2026-10-01 06:52:00 | View |
| ARS | Sep 21, 2026 | 2026-09-21 16:18:47 | View |
| DEFA14A | Sep 21, 2026 | 2026-09-21 16:18:19 | View |
| DEF 14A | Sep 21, 2026 | 2026-09-21 16:15:32 | View |
| 4 | Aug 20, 2026 | 2026-08-20 16:10:15 | View |
| 4 | Aug 20, 2026 | 2026-08-20 07:33:33 | View |
| 4 | Aug 20, 2026 | 2026-08-20 07:30:36 | View |
| 4 | Aug 20, 2026 | 2026-08-20 07:30:12 | View |
| 4 | Aug 20, 2026 | 2026-08-20 07:29:44 | View |
| 4 | Aug 20, 2026 | 2026-08-20 07:29:13 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | CAH | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 34.6x | 29.2x · sector 20.7x | Elevated |
| Forward P/E (FY27E) | 20.0x | EPS est. 12.54 | Discount |
| Price / Book | -20.6x | -14.1x | Elevated |
| Price / Sales | 0.2x | 0.1x | Elevated |
| EV / EBITDA | 18.2x | 69.5x | Discount |
| Return on equity | -59.7% | — | Weak |
| Gross margin | 3.8% | 3.5% | In line |
| Debt / Equity | -3.45 | -3.70 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 5.12 | Safe zone |
Discounted cash flow model
Current price $251.43
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 20, 26 | Mizuho | maintain | Outperform | Outperform |
| Oct 16, 26 | UBS | maintain | Buy | Buy |
| Aug 13, 26 | TD Cowen | maintain | Buy | Buy |
| Aug 13, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 13, 26 | JP Morgan | maintain | Neutral | Neutral |
| Aug 12, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Aug 12, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Aug 12, 26 | Baird | maintain | Outperform | Outperform |
| Aug 12, 26 | UBS | maintain | Buy | Buy |
FY2026 · 10-K disclosure
FY2026 · 10-K disclosure